UMIN試験ID | UMIN000039867 |
---|---|
受付番号 | R000045465 |
科学的試験名 | 前立腺癌患者におけるフレイルがQOLに与える影響(FRAQ-PC study) |
一般公開日(本登録希望日) | 2020/03/19 |
最終更新日 | 2022/12/06 12:16:39 |
日本語
前立腺癌患者におけるフレイルがQOLに与える影響(FRAQ-PC study)
英語
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
日本語
前立腺癌患者におけるフレイルがQOLに与える影響(FRAQ-PC study)
英語
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
日本語
前立腺癌患者におけるフレイルがQOLに与える影響(FRAQ-PC study)
英語
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
日本語
前立腺癌患者におけるフレイルがQOLに与える影響(FRAQ-PC study)
英語
The association of baseline frailty and quality of life in prostate cancer(FRAQ-PC study)
日本/Japan |
日本語
前立腺癌
英語
Prostate cancer
泌尿器科学/Urology |
悪性腫瘍/Malignancy
いいえ/NO
日本語
To investigate the association of baseline frailty and quality of life in prostate cancer
英語
To investigate the association of baseline frailty and quality of life in prostate cancer
安全性・有効性/Safety,Efficacy
日本語
英語
日本語
Primary outcomes: the association of baseline frailty and quality of life.
英語
Primary outcomes: the association of baseline frailty and quality of life.
日本語
Secondary outcomes: effect of frailty and QOL on overall survival in metastatic prostate cancer
英語
Secondary outcomes: effect of frailty and QOL on overall survival in metastatic prostate cancer
観察/Observational
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
日本語
英語
20 | 歳/years-old | 以上/<= |
100 | 歳/years-old | 未満/> |
男/Male
日本語
Patients with prostate cancer who can evaluate frailty
英語
Patients with prostate cancer who can evaluate frailty
日本語
Patients with prostate cancer who cannot evaluate frailty
英語
Patients with prostate cancer who cannot evaluate frailty
400
日本語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
英語
名 | Shingo |
ミドルネーム | Hatakeyama |
姓 | Hatakeyama |
日本語
Dept. of Urology, Hirosaki University Graduate School of Medicine
英語
Dept. of Urology, Hirosaki University Graduate School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou
英語
Hirosaki
0172395091
shingorilla2@gmail.com
日本語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
英語
名 | Shingo |
ミドルネーム | |
姓 | Hatakeyama |
日本語
Dept. of Urology, Hirosaki University Graduate School of Medicine
英語
Dept. of Urology, Hirosaki University Graduate School of Medicine
日本語
Urology
英語
Urology
036-8562
日本語
5 Zaifu-chou
英語
Hirosaki
0172395091
shingorilla2@gmail.com
日本語
弘前大学
英語
Dept. of Urology, Hirosaki University Graduate School of Medicine
日本語
日本語
日本語
英語
日本語
弘前大学
英語
Dept. of Urology, Hirosaki University Graduate School of Medicine
日本語
Dept. of Urology, Hirosaki University Graduate School of Medicine
日本語
その他の国の官庁/Government offices of other countries
日本語
日本
英語
日本語
英語
日本語
英語
日本語
Hirosaki University Graduate School of Medicine
英語
Hirosaki University Graduate School of Medicine
日本語
5 Zaifu-chou
英語
5 Zaifu-chou
+81172395091
rinri@hirosaki-u.ac.jp
いいえ/NO
日本語
英語
日本語
英語
2020 | 年 | 03 | 月 | 19 | 日 |
https://pubmed.ncbi.nlm.nih.gov/33079283/
最終結果が公表されている/Published
https://pubmed.ncbi.nlm.nih.gov/33079283/
369
日本語
The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.
英語
The baseline frailty and HRQOL were significantly different between the localized and metastatic disease. The baseline frailty was significantly associated with worse HRQOL in patients with PC.
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
英語
日本語
The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown.
英語
The association between baseline frailty and health-related quality of life (HRQOL) in patients with prostate cancer (PC) remains unknown.
日本語
We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool
英語
We retrospectively evaluated the association of pretreatment frailty with HRQOL in 409 patients with PC from February 2017 to April 2020. Frailty and HRQOL were evaluated using the geriatric 8 (G8) screening tool
日本語
none
英語
none
日本語
and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8<=14) on worse QOL.
英語
and QLQ-C30 questionnaire, respectively. The primary objective was comparison of G8 and QOL scores between the localized diseases (M0 group) and metastatic castration-sensitive PC (mCSPC group). Secondary objectives were to study the association of G8 and QOL scores in each group and effect of frailty (G8<=14) on worse QOL.
日本語
英語
日本語
英語
試験終了/Completed
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 06 | 日 |
2017 | 年 | 01 | 月 | 07 | 日 |
2022 | 年 | 12 | 月 | 05 | 日 |
日本語
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-UC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
In the PC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments (FRAPC study), the effect of frailty on safety and oncological outcomes 2) between the radical prostatectomy and radiation therapy in patients with localized prostate cancer (FRART-PC study), 3) among the patients with metastatic PC (FRAM-PC study), 4) the association of baseline frailty and quality of life (FRAQ-PC study), and 5) the association of baseline frailty and postoperative pain (FRAP study).
In the RCC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) in the patients with radical or partial nephrectomy (FRARN study), 2) between in the mRCC patients with molecular targeted therapy and/or immunotherapy(FRARMT study), and 4) the association of baseline frailty and quality of life (FRAQ-RCC). Also, we planned to estimate the gap between chronological and biological age using frailty (FRAGE-GAP study).
英語
This study is a part of our prospective observational study (UMIN000025057). We planned to assess the intra-group difference of frailty among the patients with prostate cancer (PC), renal cell carcinoma (RCC), and urothelial carcinoma (UC) after the development of the CGA tool.
In the UC cohort, we planned to evaluate 1) the intra-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) between the radical cystectomy and trimodal therapy in patients with MIBC (FRART-UC study), 3) between the neobladder and non-neobladder in patients with MIBC (FRAUD study), 4) in patients with upper tract urothelial carcinoma (FRAUT study), 5) metastatic urothelial carcinoma who underwent systemic chemotherapy and/or immunotherapy (FRAM-UC study), and 6) the association of baseline frailty and quality of life (FRAQ-UC study).
In the PC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments (FRAPC study), the effect of frailty on safety and oncological outcomes 2) between the radical prostatectomy and radiation therapy in patients with localized prostate cancer (FRART-PC study), 3) among the patients with metastatic PC (FRAM-PC study), 4) the association of baseline frailty and quality of life (FRAQ-PC study), and 5) the association of baseline frailty and postoperative pain (FRAP study).
In the RCC cohort, we planned to evaluate 1) the inter-group difference of frailty among the different stages and treatments, the effect of frailty on safety and oncological outcomes 2) in the patients with radical or partial nephrectomy (FRARN study), 2) between in the mRCC patients with molecular targeted therapy and/or immunotherapy(FRARMT study), and 4) the association of baseline frailty and quality of life (FRAQ-RCC). Also, we planned to estimate the gap between chronological and biological age using frailty (FRAGE-GAP study).
2020 | 年 | 03 | 月 | 18 | 日 |
2022 | 年 | 12 | 月 | 06 | 日 |
日本語
https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000045465
英語
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045465
研究計画書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ仕様書 | |
---|---|
登録日時 | ファイル名 |
研究症例データ | |
---|---|
登録日時 | ファイル名 |